Two research questions to guide future studies arose from our findings: if anti-IL-5 mAb for CRSwNP should be dose-adjusted by weight, and if the indication of anti-IL-5 mAb for CRSwNP should always require a high baseline blood eosinophil. The gene discussed is IL5; the disease is chronic rhinosinusitis with nasal polyps.